TLSI Stock Forecast & Price Target

TriSalus Life Sciences is attractive because TriNav is addressing a large, under-penetrated liver embolization market with a differentiated PEDD platform that has shown better tumor delivery, stronger real-world outcomes, and durable reimbursement support through permanent C-codes. The 2025 revenue of $45.2M, 53% YoY growth, and FY26 guidance of $54M-$57M, alongside 2Q26 revenue of $11.4M and 86.8% gross margin, suggest a commercial business with meaningful operating leverage as the expanded sales force matures. TriNav Advance clearance is especially important because it removes a key device limitation, potentially lifting share from roughly 10% to 15%-20% of the liver embolization market while also opening adjacent opportunities that could expand the TAM from about $480M toward nearly $2.5B.

TriSalus Life Sciences is under pressure because its valuation case relies heavily on continued TriNav adoption, yet 1Q26 revenue of $8.9M fell 2.9% YoY and FY26 guidance was cut to $54M-$57M after the TriNav Advance 510(k) delay and a commercial reset that disrupted roughly 40% of territories. The company is also highly concentrated, with substantially all revenue coming from one device family, while reimbursement is uncertain, physician awareness remains limited, and the PEDD evidence base is still largely retrospective and single-center. Incremental growth opportunities are also less certain because GAE depends on third-party embolic approval, no embolic agent carries a US label for the procedure, and the business is not yet profitable, increasing dilution risk if additional capital is needed.